Asianet NewsableAsianet Newsable

Haryana Health minister Anil Vij administered trial dose of COVID-19 vaccine Covaxin

 Anil Vij was administered the trial dose at the Civil Hospital at Ambala Cantt, the BJP leader said on Twitter.
 

Haryana Health minister Anil Vij administered trial dose of COVID-19 vaccine Covaxin-dnm
Author
Bengaluru, First Published Nov 20, 2020, 1:25 PM IST

Haryana Health Minister Anil Vij on Friday administered a trial dose of coronavirus vaccine candidate Covaxin, at a hospital in Ambala. He had offered to be the first volunteer for the third phase trial of Covaxin, which started in the state today.

Covaxin is being developed indigenously by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

Vij was administered the trial dose at the Civil Hospital at Ambala Cantt, the BJP leader said on Twitter.

Vij, who is an MLA from Ambala Cantt, had on Wednesday said the third phase of trial of Covaxin will begin in the state on November 20. Taking to twitter, Ani Vij said: "I will be administered a trial dose of Coronavirus vaccine #Covaxin a Bharat Biotech product Tomorrow at 11 am at Civil hospital, Ambala Cantt under the expert supervision of a team of doctors from PGI Rohtak and Health Department. I have volunteered to take the trial dose."

On 18 November, the Ambala Cantt MLA had said the third phase of trial of Covaxin will begin in Haryana on 20 November and had offered to be the first volunteer to get vaccinated.

Last month, the Covaxin said it had successfully completed interim analysis of Phase 1 and 2 trials and is initiating Phase 3 trials.

The third phase trials will involve nearly 26,000 volunteers across India and will be conducted in partnership with ICMR. It is the largest clinical trial conducted for a Covid-19 vaccine in India.

Bharat Biotech had on Monday said the Phase 3 trial of Covaxin will involve 26,000 volunteers across 25 centres in India and is being conducted in partnership with the ICMR. It is the largest clinical trial conducted for a COVID-19 vaccine in India.

This is India's first Phase 3 efficacy study for a COVID-19 vaccine, and the largest Phase 3 efficacy trial ever conducted.

Follow Us:
Download App:
  • android
  • ios